Relation Expression of Eestrogen Reseptor and Ki67 in Invasive Ductal Carcinoma Breast Cancer


  • Christian B Departement of Surgical oncology1, Pathology Anatomy
  • Daniel Sampepajung Departement of Surgical oncology1, Pathology Anatomy
  • Prihantono Prihantono Departement of Surgical oncology1, Pathology Anatomy
  • Berti Nelwan Medical Faculty Hasanuddin University of Makassar
  • Burhanuddin Bahar Faculty of Public Health, Hasanuddin University, Makassar


Expression ER and Ki67, Carcinoma breast cancer.


Estrogen are potent mitogenic stimuli that share important properties in the control of cellular proliferation. Increased expression and/or activity of estrogen reseptor (ER) result in aberrant activation of downstream signaling pathways including cAMP/PKA, MAPK/ERK and PI3K/AKT. The importance of estrogen and as a signaling axis in cancer development, progression and metastasis is highlighted by its effects on cancer cells, notably proliferation.


Desantis C, Ma, J., Bryan, L. & Jemal, A. . Breast cancer statistics, 2013. , . CA: a cancer journal for clinicians. 2014.;64, .52-62.

Aaltonen KE, Rosendahl AH, Olsson H, Malmstr

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a cancer journal for clinicians. 2005;55(2):74-108.

Murray S, Briasoulis, E., Linardou, H., Bafaloukos, D. & Papadimitriou, C. . Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. . Cancer treatment reviews, . 2012. ;38, :890-903.

Yaghjyan L, Colditz GA. Estrogens in the breast tissue: a systematic review. Cancer Causes & Control. 2011;22(4):529-40.

Zhang X, Tworoger SS, Eliassen AH, Hankinson SE. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast cancer research and treatment. 2013;137(3):883-92.

Marino M, Acconcia F, Bresciani F, Weisz A, Trentalance A. Distinct nongenomic signal transduction pathways controlled by 17?-estradiol regulate DNA synthesis and cyclin D1 gene transcription in HepG2 cells. Molecular biology of the cell. 2002;13(10):3720-9.

Kenny Fs, Hui R, Musgrove Ea, Gee Jm, Blamey Rw, Nicholson Ri, et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clinical cancer research. 1999;5(8):2069-76.

Jakowlew SB, Breathnach R, Jeltsch J-M, Masiakowski P, Chambon P. Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic acids research. 1984;12(6):2861-78.

Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. The Journal of Immunology. 1984;133(4):1710-5.

Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer research. 2005;25(3A):1719-23.

Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol. 2011;9(1):131.

Farhat GN, Cummings SR, Chlebowski RT, Parimi N, Cauley JA, Rohan TE, et al. Sex Hormone Levels and Risks of Estrogen Receptor

Woolcott CG, Shvetsov YB, Stanczyk FZ, Wilkens LR, White KK, Caberto C, et al. Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the Multiethnic Cohort Study. Endocrine-related cancer. 2010;17(1):125-34.

Kim J-Y, Han W, Moon H-G, Ahn SK, Kim J, Lee JW, et al. Prognostic effect of preoperative Serum estradiol level in postmenopausal breast cancer. BMC cancer. 2013;13(1):503.

Shapochka D, Zaletok S, Gnidyuk M. Relationship between NF-?B, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer. Experimental oncology. 2012;34(4):358-63.


Huang P, Liu L-X. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-? Expression in Invasive Ductal Breast Cancer Patients and Correlations with Prognosis. Asian Pacific Journal of Cancer Prevention. 2015;16(2):823-9.

Bouzubar N, Walker K, Griffiths K, Ellis I, Elston C, Robertson J, et al. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. British journal of cancer. 1989;59(6):943.

Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi M, Marco B, et al. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer research. 1995;16(5B):3105-10.

Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC cancer. 2011;11(1):486.

Ingolf JB, Russalina M, Simona M, Julia R, Gilda S, Bohle RM, et al. Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy? BioMed research international. 2014;2014:628217.

Inwald E, Klinkhammer-Schalke M, Hofst

de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. British journal of cancer. 2007;96(10):1504-13.

Dowsett M, Nielsen TO, A

Luporsi E, Andr

DeCensi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, et al. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Annals of oncology. 2011;22(3):582-7.

Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. Journal of clinical oncology. 2005;23(28):7212-20.

Criscitiello C, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, et al. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. Breast. 2014;23(1):69-75.

Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, Van de Vijver M. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. British journal of Cancer. 2003;88(3):406-12.

Honkoop A, Van Diest P, De Jong J, Linn S, Giaccone G, Hoekman K, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. British journal of cancer. 1998;77(4):621.

McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science. 2002;296(5573):1642-4.




How to Cite

B, C., Sampepajung, D., Prihantono, P., Nelwan, B., & Bahar, B. (2016). Relation Expression of Eestrogen Reseptor and Ki67 in Invasive Ductal Carcinoma Breast Cancer. International Journal of Sciences: Basic and Applied Research (IJSBAR), 30(5), 106–113. Retrieved from